- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: Ipatasertib is an inhibitor of the AKT family of protein kinases . The synthesis of ipatasertib is described in patent WO2008006040  and  where it is compound 28 (the Supporting Information for this article contains activity data for compound 28 against a full kinase screening panel). This compound is also represented on PubChem by CID 23649210.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Blake JF, Xu R, Bencsik JR, Xiao D, Kallan NC, Schlachter S, Mitchell IS, Spencer KL, Banka AL, Wallace EM et al.. (2012)
Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.
J Med Chem, 55 (18): 8110-27. [PMID:22934575]
2. Mitchell IS, Blake JF, Xu R, Kallan NC, Xiao D, Spencer KL, Bencsik JR, Liang J, Safina B, Zhang B et al.. (2010)
Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors.
Patent number: WO2008006040. Assignee: Array Biopharma Inc and Genentech Inc. Priority date: 06/06/2006. Publication date: 10/01/2010.